Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A09065 | Pages: 262 | Charts: 56 | Tables: 130 |
The global gene therapy cell culture media market size accounted for $122.60 million in 2019, and is expected to reach $278.96 million by 2027, registering a CAGR of 10.6% from 2020 to 2027. Gene therapies are treatments applicable to a broad range of diseases. They radically treat the cause of the diseases instead of only relieving the symptoms. Furthermore, they may be effective on a wide range of previously untreated diseases, such as hematological, ocular, neurodegenerative diseases, and several cancers. Gene therapy cell culture media consists of important nutrients that provide ample energy to regulate healthy cell cycle. Moreover, it contains bovine serum, animal-derived nutrients, and growth factors like EGF, FGF, IGF, and PDGF. Different culture media are available in the market for various cell cultures to survive and grow in their incubation environment. The culture media market is anticipated to grow considerably in the near future, owing to different factors such as increase in investments and funding for R&D and innovation in life sciences, especially biopharmaceutical products.
Get more information on this report : Request Sample Pages
The major factors that contribute toward the growth of the gene therapy cell culture media market include rise in R&D investments, and growth in awareness regarding gene therapy. Furthermore, factors such as increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer fuel the growth of the market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the gene therapy cell culture media market growth. The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe.
[MEDIATYPEGRAPH]
Get more information on this report : Request Sample Pages
Due to COVID-19 pandemic, the gene therapy cell culture media companies are largely protected from economic disruption, owing to increase in demand for media such as improved protein-free media for growth and production of viral vectors. Rise in demand for COVID vaccine through gene and cell therapy propels the market growth. Furthermore, many gene therapy companies may see the opportunity to find vaccines for Covid-19 as life support which increases the demand for gene therapy cell culture media market as its wider use in clinical trials.
The gene therapy cell culture media market is segmented on the basis of media type, viral vectors type, end user, and region. By media type is further divided into serum containing media, serum free media, stem cell media, specialty media, chemically defined media, lysogeny broth, custom media, and others. By viral vectors type, the market is divided into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. By end user, it is classified into biotechnology & pharmaceutical industry, academic institute, research laboratory, and others. Region wise, it is analyzed across North America Europe, Asia-Pacific, and LAMEA.
[VIRALVECTORSTYPEGRAPH]
Get more information on this report : Request Sample Pages
Presently, on the basis of media type, the chemical defined media is the major revenue contributor, and is projected to grow significantly during the forecast period. This is attributed to the repeated purchase of consumables and increased funding for cell-based research. By media type is further divided into serum containing media, serum free media, stem cell media, specialty media, chemically defined media, lysogeny broth, custom media, and others. In addition, the viral vectors are divided into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others.
Depending on end user, the gene therapy cell culture media market is classified into biotechnology & pharmaceutical industry, academic institute, research laboratory, and others. Pharmaceutical & Biotechnology industry segment is the major shareholder in the gene therapy cell culture media market, owing to expansion of major pharmaceutical companies, increase in government support and ethical acceptance of gene therapy for cancer treatment.
[ENDUSERGRAPH]
Get more information on this report : Request Sample Pages
Asia-Pacific presents lucrative opportunities for key players operating in the gene therapy cell culture media market, owing to awareness regarding gene therapy for cancer treatment, and rise in prevalence of cancer. The other factors that boost the growth of the market include surge in research funding in the region. Furthermore, focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the cell culture market in the region.
The key players profiled in this report include Fujifilm Holdings Corporation, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd, Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Takara Holdings Inc., Novartis International AG, and Bio-Techne Corporation.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.1.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in R&D investments
3.5.1.2.Growth in awareness regarding gene therapy
3.5.1.3.Increase in advancements associated gene therapy
3.5.1.4.Increase in prevalence of cancer
3.5.2.Restraints
3.5.2.1.Dearth of skilled professionals
3.5.2.2.High cost associated with gene therapies
3.5.2.3.Ethical & scientific concerns associated with culture media
3.5.3.Opportunity
3.5.3.1.Untapped potential of the emerging economies
3.6.Impact Analysis of COVID-19 on Gene Therapy Cell Culture Media Market
CHAPTER 4:GENE THERAPY CELL CULTURE MEDIA MARKET, BY
MEDIA TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Serum-containing media
4.2.1.Market size and forecast, by region
4.2.2.Market analysis by country
4.3.Serum-free media
4.3.1.Market size and forecast, by region
4.3.2.Market analysis by country
4.4.Stem cell media
4.4.1.Market size and forecast, by region
4.4.2.Market analysis by country
4.5.Specialty media
4.5.1.Market size and forecast, by region
4.5.2.Market analysis by country
4.6.Chemically defined media
4.6.1.Market size and forecast, by region
4.6.2.Market analysis by country
4.7.Lysogeny broth
4.7.1.Market size and forecast, by region
4.7.2.Market analysis by country
4.8.Custom media
4.8.1.Market size and forecast, by region
4.8.2.Market analysis by country
4.9.Other media
4.9.1.Market size and forecast, by region
4.9.2.Market analysis by country
CHAPTER 5:GENE THERAPY CELL CULTURE MEDIA MARKET, BY
VIRAL VECTORS TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Retroviruses
5.2.1.Market size and forecast, by region
5.2.2.Market analysis by country
5.3.Lentiviruses
5.3.1.Market size and forecast, by region
5.3.2.Market analysis by country
5.4.Adenoviruses
5.4.1.Market size and forecast, by region
5.4.2.Market analysis by country
5.5.Adeno associated virus
5.5.1.Market size and forecast, by region
5.5.2.Market analysis by country
5.6.Herpes simplex virus
5.6.1.Market size and forecast, by region
5.6.2.Market analysis by country
5.7.Poxvirus
5.7.1.Market size and forecast, by region
5.7.2.Market analysis by country
5.8.Vaccinia virus
5.8.1.Market size and forecast, by region
5.8.2.Market analysis by country
5.9.Others
5.9.1.Market size and forecast, by region
5.9.2.Market analysis by country
CHAPTER 6:GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Pharmaceutical & biotechnology Industries
6.2.1.Market size and forecast, by region
6.2.2.Market analysis by country
6.3.Research Laboratories
6.3.1.Market size and forecast, by region
6.3.2.Market analysis by country
6.4.Academic Institutions
6.4.1.Market size and forecast, by region
6.4.2.Market analysis by country
6.5.Others
6.5.1.Market size and forecast, by region
6.5.2.Market analysis by country
CHAPTER 7:GENE THERAPY CELL CULTURE MEDIA MARKET, BY REGION
7.1.OVERVIEW
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.North America cell culture market, by country
7.2.2.1.U.S. gene therapy cell culture media market, by media type
7.2.2.2.U.S. gene therapy cell culture media market, by viral vectors type
7.2.2.3.U.S. gene therapy cell culture media market, by end user
7.2.2.4.Canada gene therapy cell culture media market, by media type
7.2.2.5.Canada gene therapy cell culture media market, by viral
vectors type
7.2.2.6.Canada gene therapy cell culture media market, by end user
7.2.2.7.Mexico gene therapy cell culture media market, by media type
7.2.2.8.Mexico gene therapy cell culture media market, by viral vectors type
7.2.2.9.Mexico gene therapy cell culture media market, by end user
7.2.3.North America gene therapy cell culture media market, by media type
7.2.4.North America gene therapy cell culture media market, by viral
vectors type
7.2.5.North America gene therapy cell culture media market, by end user
7.3.Europe
7.3.1.Key market trends and opportunities
7.3.2.Europe gene therapy cell culture media market, by country
7.3.2.1.Germany gene therapy cell culture media market, by media type
7.3.2.2.Germany gene therapy cell culture media market, by viral
vectors type
7.3.2.3.Germany gene therapy cell culture media market, by end user
7.3.2.4.France gene therapy cell culture media market, by media type
7.3.2.5.France gene therapy cell culture media market, by viral vectors type
7.3.2.6.France gene therapy cell culture media market, by end user
7.3.2.7.UK gene therapy cell culture media market, by media type
7.3.2.8.UK gene therapy cell culture media market, by viral vectors type
7.3.2.9.Uk gene therapy cell culture media market, by end user
7.3.2.10.Italy gene therapy cell culture media market, by media type
7.3.2.11.Italy gene therapy cell culture media market, by viral vectors type
7.3.2.12.Italy gene therapy cell culture media market, by end user
7.3.2.13.Spain gene therapy cell culture media market, by media type
7.3.2.14.Spain gene therapy cell culture media market, by viral vectors type
7.3.2.15.Spain gene therapy cell culture media market, by end user
7.3.2.16.Rest of Europe gene therapy cell culture media market,
by media type
7.3.2.17.Rest of Europe gene therapy cell culture media market,
by viral vectors type
7.3.2.18.Rest of Europe gene therapy cell culture media market, by end user
7.3.3.Europe gene therapy cell culture media market, by media type
7.3.4.Europe gene therapy cell culture media market, by viral vectors type
7.3.5.Europe gene therapy cell culture media market, by end user
7.4.Asia-Pacifi
7.4.1.Key market trends and opportunities
7.4.2.Asia-Pacific gene therapy cell culture media market, by country
7.4.2.1.China gene therapy cell culture media market, by media type
7.4.2.2.China gene therapy cell culture media market, by viral vectors type
7.4.2.3.China gene therapy cell culture media market, by end user
7.4.2.4.Japan gene therapy cell culture media market, by media type
7.4.2.5.Japan gene therapy cell culture media market, by viral vectors type
7.4.2.6.Japan gene therapy cell culture media market, by end user
7.4.2.7.Australia gene therapy cell culture media market, by media type
7.4.2.8.Australia gene therapy cell culture media market, by viral
vectors type
7.4.2.9.Australia gene therapy cell culture media market, by end user
7.4.2.10.India gene therapy cell culture media market, by media type
7.4.2.11.India gene therapy cell culture media market, by viral vectors type
7.4.2.12.India gene therapy cell culture media market, by end user
7.4.2.13.South Korea gene therapy cell culture media market, by media type
7.4.2.14.South Korea gene therapy cell culture media market, by viral
vectors type
7.4.2.15.South Korea gene therapy cell culture media market, by end user
7.4.2.16.Rest of Asia-Pacific gene therapy cell culture media market,
by media type
7.4.2.17.Rest of Asia-Pacific gene therapy cell culture media market,
by viral vectors type
7.4.2.18.Rest of Asia- Pacific gene therapy cell culture media market,
by end user
7.4.3.Asia- Pacific gene therapy cell culture media market, by media type
7.4.4.Asia- Pacific gene therapy cell culture media market, by
viral vectors type
7.4.5.Asia- Pacific gene therapy cell culture media market, by end user
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.LAMEA gene therapy cell culture media market, by country
7.5.2.1.Brazil gene therapy cell culture media market, by media type
7.5.2.2.Brazil gene therapy cell culture media market, by viral vectors type
7.5.3.Brazil gene therapy cell culture media market, by end user
7.5.3.1.Saudi Arabia gene therapy cell culture media market,
by media type
7.5.3.2.Saudi Arabia gene therapy cell culture media market, by
viral vectors type
7.5.4.Saudi Arabia gene therapy cell culture media market, by end user
7.5.4.1.South Africa gene therapy cell culture media market, by media type
7.5.4.2.South Africa gene therapy cell culture media market, by viral
vectors type
7.5.5.South Africa gene therapy cell culture media market, by end user
7.5.5.1.Rest of LAMEA gene therapy cell culture media market,
by media type
7.5.5.2.Rest of LAMEA gene therapy cell culture media market, by
viral vectors type
7.5.6.REST OF LAMEA gene therapy cell culture media market, by end user
7.5.7.LAMEA gene therapy cell culture media market, by media type
7.5.8.LAMEA gene therapy cell culture media market, by viral vectors type
7.5.9.LAMEA gene therapy cell culture media market, by end user
CHAPTER 8:COMPANY PROFILES
8.1.BIO-TECHNE CORPORATION
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Operating product portfolio
8.1.5.Business performance
8.2.DANAHER CORPORATION (CYTIVA)
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.FUJIFILM HOLDINGS CORPORATION (FUJIFILM IRVINE SCIENTIFIC)
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.HIMEDIA LABORATORIES
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.5.LONZA GROUP LTD
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Operating product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.MERCK KGAA
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.NOVARTIS INTERNATIONAL AG
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.SARTORIUS AG
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.THERMO FISHER SCIENTIFIC, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.TAKARA HOLDINGS INC. (TAKARA BIO INC.)
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.GENE THERPAY CELL CULTURE MEDIA MARKET BY MEDIA TYPE 2019-2027, ($MILLION)
TABLE 02.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SERUM CONTAINING MEDIA, BY REGION
2019–2027($MILLION)
TABLE 03.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SERUM FREE MEDIA, BY REGION
2019–2027($MILLION)
TABLE 04.GENE THERAPY CELL CULTURE MEDIA MARKET FOR STEM CELL MEDIA, BY REGION
2019–2027($MILLION)
TABLE 05.GENE THERAPY CELL CULTURE MEDIA MARKET FOR SPECIALTY MEDIA, BY REGION
2019–2027($MILLION)
TABLE 06.GENE THERAPY CELL CULTURE MEDIA MARKET FOR CHEMICALLY DEFINED MEDIA,
BY REGION 2019–2027($MILLION)
TABLE 07.GENE THERAPY CELL CULTURE MEDIA MARKET FOR LYSOGENY BROTH, BY REGION
2019–2027($MILLION)
TABLE 08.GENE THERAPY CELL CULTURE MEDIA MARKET FOR CUSTOM MEDIA, BY REGION
2019–2027($MILLION)
TABLE 09.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHER MEDIA, BY REGION
2019–2027($MILLION)
TABLE 10.GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 11.GENE THERAPY CELL CULTURE MEDIA MARKET FOR RETROVIRUSES, BY REGION
2019–2027($MILLION)
TABLE 12.GENE THERAPY CELL CULTURE MEDIA MARKET FOR LENTIVIRUSES, BY REGION
2019–2027($MILLION)
TABLE 13.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ADENOVIRUSES, BY REGION
2019–2027($MILLION)
TABLE 14.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ADENO ASSOCIATED VIRUS, BY REGION
2019–2027($MILLION)
TABLE 15.GENE THERAPY CELL CULTURE MEDIA MARKET FOR HERPES SIMPLEX VIRUS, BY REGION
2019–2027($MILLION)
TABLE 16.GENE THERAPY CELL CULTURE MEDIA MARKET FOR POXVIRUS, BY REGION 2019–2027($MILLION)
TABLE 17.GENE THERAPY CELL CULTURE MEDIA MARKET FOR VACCINIA VIRUS, BY REGION
2019–2027($MILLION)
TABLE 18.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHERS, BY REGION 2019–2027($MILLION)
TABLE 19.GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019-2027 ($MILLION)
TABLE 20.GENE THERAPY CELL CULTURE MEDIA MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY
INDUSTRIES, BY REGION 2019–2027($MILLION)
TABLE 21.GENE THERAPY CELL CULTURE MEDIA MARKET FOR RESEARCH LABORATORIES, BY REGION
2019–2027 ($MILLION)
TABLE 22.GENE THERAPY CELL CULTURE MEDIA MARKET FOR ACADEMIC INSTITUTIONS, BY REGION
2019–2027 ($MILLION)
TABLE 23.GENE THERAPY CELL CULTURE MEDIA MARKET FOR OTHERS, BY REGION 2019–2027 ($MILLION)
TABLE 24.GENE THERAPY CELL CULTURE MEDIA MARKET REVENUE, BY REGION, 2019–2027($MILLION)
TABLE 25.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY,
2019–2027($MILLION)
TABLE 26.U.S. GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 27.U.S. GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 28.U.S. GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 29.CANADA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 30.CANADA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 31.CANADA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 32.MEXICO GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 33.MEXICO GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 34.MEXICO GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 35.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 36.NORTH AMERICA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 37.NORTH AMERICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)
TABLE 38.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 39.GERMANY GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 40.GERMANY GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 41.GERMANY GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 42.FRANCE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 43.FRANCE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 44.FRANCE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 45.UK GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 46.UK GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 47.UK GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 48.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 49.ITALY GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 50.ITALY GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 51.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 52.SPAIN GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 53.SPAIN GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 54.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 55.REST OF EUROPE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 56.REST OF EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)
TABLE 57.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 58.EUROPE GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 59.EUROPE GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 60.ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 61.CHINA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 62.CHINA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 63.CHINA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 64.JAPAN GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 65.JAPAN GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 66.JAPAN GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 67.AUSTRALIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 68.AUSTRALIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 69.AUSTRALIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 70.INDIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 71.INDIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE 2019-2027, ($MILLION)
TABLE 72.INDIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 73.SOUTH KOREA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 74.SOUTH KOREA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 75.SOUTH KOREA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 76.REST OF ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 77.REST OF ASIA-PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 78.REST OF ASIA PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)
TABLE 79.ASIA-PACIFIC GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 80.ASIA PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 81.ASIA- PACIFC GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 82.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 83.BRAZIL GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 84.BRAZIL GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 85.BRAZIL GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 86.SAUDI ARABIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 87.SAUDI ARABIA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 88.SAUDI ARABIA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 89.SOUTH AFRICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 90.SOUTH AFRICA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 91.SOUTH AFRICA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)
TABLE 92.REST OF LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE,
2019–2027($MILLION)
TABLE 93.REST OF LAMEA GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 94.REST OF LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER,
2019–2027($MILLION)20
TABLE 95.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY MEDIA TYPE, 2019–2027($MILLION)
TABLE 96.ASIA PACIFIC GENE THERPAY CELL CULTURE MEDIA MARKET BY VIRAL VECTOR TYPE
2019-2027, ($MILLION)
TABLE 97.LAMEA GENE THERAPY CELL CULTURE MEDIA MARKET, BY END USER, 2019–2027($MILLION)
TABLE 98.BIO-TECHNE: COMPANY SNAPSHOT
TABLE 99.OPERATING BUSINESS SEGMENT
TABLE 100.BIO-TECHNE: PRODUCT PORTFOLIO
TABLE 101.DANAHER: COMPANY SNAPSHOT
TABLE 102.DANAHER: OPERATING SEGMENT
TABLE 103.GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 104.FUJIFILM: COMPANY SNAPSHOT
TABLE 105.FUJIFILM: OPERATING SEGMENTS
TABLE 106.FUJIFILM: PRODUCT PORTFOLIO
TABLE 107.HIMEDIA: COMPANY SNAPSHOT
TABLE 108.HIMEDIA:OPERATING PRODUCT SEGMENT
TABLE 109.HIMEDIA: PRODUCT PORTFOLIO
TABLE 110.LONZA: COMPANY SNAPSHOT
TABLE 111.PRODUCT PORTFOLIO
TABLE 112.LONZA: PRODUCT PORTFOLIO
TABLE 113.SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.MERCK: COMPANY SNAPSHOT
TABLE 115.MERCK: OPERATING SEGMENTS
TABLE 116.MERCK: PRODUCT PORTFOLIO
TABLE 117.SARTORIUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118.NOVARTIS: COMPANY SNAPSHOT
TABLE 119.NOVARTIS: OPERATING SEGMENTS
TABLE 120.NOVARTIS: PRODUCT PORTFOLIO
TABLE 121.SARTORIUS: COMPANY SNAPSHOT
TABLE 122.SARTORIUS: OPERATING BUSINESS SEGMENTS
TABLE 123.SARTORIUS: PRODUCT PORTFOLIO
TABLE 124.THERMO FISHER: COMPANY SNAPSHOT
TABLE 125.THERMO FISHER.: OPERATING SEGMENTS
TABLE 126.THERMO FISHER.: PRODUCT PORTFOLIO
TABLE 127.THERMO FISHER SCIENTIFIC : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 128.TAKARA GROUP: COMPANY SNAPSHOT
TABLE 129.TAKARA GROUP: OPERATING SEGMENTS
TABLE 130.TAKARA GROUP: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GENE THERAPY CELL CULTURE MEDIA MARKETSEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020*
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020*
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.LOW BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 12.GENE THERAPY PIPELINE VOLUME, PRECLINICAL THROUGH PRE-REGISTRATION PHASE, 1995–2018
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
SERUM CONTAINING MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
SERUM FREE MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
STEM CELL MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
SPECIALTY MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
CHEMICALLY DEFINED MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
LYSOGENY BROTH, BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
CUSTOM MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
OTHER MEDIA, BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
RETROVIRUSES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
LENTIVIRUSES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
ADENOVIRUSES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
ADENO ASSOCIATED VIRUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
HERPES SIMPLEX VIRUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
POXVIRUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
VACCINIA VIRUS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
RESEARCH LABORATORIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF CELL CULTURE MARKET FOR ACADEMIC INSTITUTIONS,
BY COUNTRY, 2019 & 2027 (%)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY CELL CULTURE MEDIA MARKET FOR
OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 33.BIO-TECHNE: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.BIO-TECHNE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.BIO-TECHNE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.DANAHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.DANAHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.DANAHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.FUJIFILM: NET SALES, 2018–2020 ($MILLION)
FIGURE 40.FUJIFILM: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 41.LONZA: NET SALES, 2017–2019 ($MILLION)
FIGURE 42.LONZA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 43.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 45.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 46.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 47.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 48.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 49.SARTORIUS: NET SALES, 2017–2019 ($MILLION)
FIGURE 50.SARTORIUS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 51.SARTORIUS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 52.THERMO FISHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.THERMO FISHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 54.THERMO FISHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 55.TAKARA GROUP: NET SALES, 2017–2019 ($MILLION)
FIGURE 56.TAKARA GROUP: REVENUE SHARE, BY SEGMENT, 2019 (%)
